Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) Exhibited Potent Anti-Fibrotic Activity in NASH and CKD Studies

Algernon Pharmaceuticals Inc., formerly known as Breathtec, a UF startup, is pleased to report that its lead drugs for non-alcoholic steatohepatitis (NASH) and chronic kidney disease (CKD) Bemethyl (NP-135) and Bromantane (NP-160), exhibited highly statistically significant anti-fibrotic activity and outperformed known anti-fibrotic agents Telmisartan and Cenicriviroc.

“We are planning off-label phase II clinical trials for both drugs and pending the data, the company will begin the process for regulatory approval with the USFDA,” said Christopher J. Moreau, CEO of Algernon. “We also intend to publish our data in a peer-reviewed journal shortly. It is intriguing to think that drugs developed by the Soviet Union during the Cold War could end up being viable treatment options for both NASH & CKD on a global scale.”

Learn more about Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) Exhibited Potent Anti-Fibrotic Activity in NASH and CKD Studies.